Erschienen in:

01.07.2010 | Research Articles

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01

verfasst von: Joaquim Bellmunt, Pablo Maroto-Rey, José M. Trigo, Joan Carles, Vicente Guillem, José A. López-Martín, Antonio Antón-Torres, Leyrer Urruticoechea

Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2010